Organon & Co. Stock News

The trading price of Organon & Co. (NYSE:OGN) floating higher at last check on Wednesday, February 16, closing at $35.86, 1.82% higher than its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << Traders who pay close attention to intraday price movement should know that it … Organon & Co.’s Stock Gains 1.82%, But It May Still Be Worth Investing In. Read More »

Organon (NYSE:OGN) is scheduled to announce Q4 earnings results on Thursday, February 17th, before market open.The consensus EPS Estimate is $1.27 and the consensus Revenue Estimate…

Organon (OGN) announced on Wednesday that the company acquired the rights for Marvelon and Mercilon combined oral hormonal daily contraceptive pills in China (including Hong Kong and…

If there''s one thing recent macroeconomic and stock market turbulence should reteach us, it''s that the best blue-chip dividend stocks never go out of style. And the Dow''s best dividend stocks are proving that handily so far in 2022. True, inflation is advancing at the fastest pace in four decades, and the market is seething with anxiety over impending interest rate hikes. Yet the top-rated dividend payers among the 30 Dow Jones stocks are beating the market so far this year and should continue to give income investors some much-needed peace of mind. SEE MORE The Pros Picks: 22 Top Stocks to Invest In for 2022 Many of the Dow''s best dividend stocks also happen to be dividend growth stalwarts. Quite a few names in this elite bastion of 30 blue-chip equities are members of the S&P 500 Dividend Aristocrats an index of 66 best dividend stocks that have increased their payouts for at least 25 consecutive years. It''s also noteworthy that the Dow Jones'' best dividend stocks hail from sectors that hold up well when inflation runs hot .

Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.

Smart Beta ETF report for XPH

Organon is a spin-off from Merck that is focused on women's health, biosimilars, and established brands. The company's biosimilars are reporting growth and should see additional uptake. It has only be

Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Viatris has demonstrated stable business performance, and key synergies could be catalysts for 2022. Learn more about VTRS stock and its future outlook here.

Organon & Co. (OGN) CEO Kevin Ali on JPMorgan 40th Annual Healthcare Conference (Transcript)

The only two winners were GXO Logistics and DT Midstream. Here's why it can take six months to three years for a spinoff to outperform.